KR101857142B1 - 암에 대항하는 베바시주맙과 조합된 파클리탁셀 및 알부민의 나노입자 - Google Patents

암에 대항하는 베바시주맙과 조합된 파클리탁셀 및 알부민의 나노입자 Download PDF

Info

Publication number
KR101857142B1
KR101857142B1 KR1020177002657A KR20177002657A KR101857142B1 KR 101857142 B1 KR101857142 B1 KR 101857142B1 KR 1020177002657 A KR1020177002657 A KR 1020177002657A KR 20177002657 A KR20177002657 A KR 20177002657A KR 101857142 B1 KR101857142 B1 KR 101857142B1
Authority
KR
South Korea
Prior art keywords
taxane
effective amount
composition
paclitaxel
albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177002657A
Other languages
English (en)
Korean (ko)
Other versions
KR20170016017A (ko
Inventor
네일 피. 데사이
패트릭 순-쉬옹
Original Assignee
아브락시스 바이오사이언스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아브락시스 바이오사이언스, 엘엘씨 filed Critical 아브락시스 바이오사이언스, 엘엘씨
Publication of KR20170016017A publication Critical patent/KR20170016017A/ko
Application granted granted Critical
Publication of KR101857142B1 publication Critical patent/KR101857142B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020177002657A 2006-11-06 2007-11-06 암에 대항하는 베바시주맙과 조합된 파클리탁셀 및 알부민의 나노입자 Active KR101857142B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/594,417 US20070166388A1 (en) 2005-02-18 2006-11-06 Combinations and modes of administration of therapeutic agents and combination therapy
US11/594,417 2006-11-06
PCT/US2007/023446 WO2008057562A1 (en) 2006-11-06 2007-11-06 Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157014446A Division KR20150065957A (ko) 2006-11-06 2007-11-06 암에 대항하는 베바시주맙과 조합된 파클리탁셀 및 알부민의 나노입자

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187002044A Division KR20180012339A (ko) 2006-11-06 2007-11-06 암에 대항하는 베바시주맙과 조합된 파클리탁셀 및 알부민의 나노입자

Publications (2)

Publication Number Publication Date
KR20170016017A KR20170016017A (ko) 2017-02-10
KR101857142B1 true KR101857142B1 (ko) 2018-05-14

Family

ID=39111840

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020177002657A Active KR101857142B1 (ko) 2006-11-06 2007-11-06 암에 대항하는 베바시주맙과 조합된 파클리탁셀 및 알부민의 나노입자
KR1020187002044A Withdrawn KR20180012339A (ko) 2006-11-06 2007-11-06 암에 대항하는 베바시주맙과 조합된 파클리탁셀 및 알부민의 나노입자
KR1020097011640A Ceased KR20090087906A (ko) 2006-11-06 2007-11-06 암에 대항하는 베바시주맙과 조합된 파클리탁셀 및 알부민의 나노입자
KR1020157014446A Ceased KR20150065957A (ko) 2006-11-06 2007-11-06 암에 대항하는 베바시주맙과 조합된 파클리탁셀 및 알부민의 나노입자

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020187002044A Withdrawn KR20180012339A (ko) 2006-11-06 2007-11-06 암에 대항하는 베바시주맙과 조합된 파클리탁셀 및 알부민의 나노입자
KR1020097011640A Ceased KR20090087906A (ko) 2006-11-06 2007-11-06 암에 대항하는 베바시주맙과 조합된 파클리탁셀 및 알부민의 나노입자
KR1020157014446A Ceased KR20150065957A (ko) 2006-11-06 2007-11-06 암에 대항하는 베바시주맙과 조합된 파클리탁셀 및 알부민의 나노입자

Country Status (22)

Country Link
US (1) US20070166388A1 (enExample)
EP (3) EP3108885A1 (enExample)
JP (3) JP5931323B2 (enExample)
KR (4) KR101857142B1 (enExample)
CN (2) CN101573108A (enExample)
AU (1) AU2007317859B2 (enExample)
BR (1) BRPI0718528A2 (enExample)
CA (1) CA2668607A1 (enExample)
CY (2) CY1115271T1 (enExample)
DK (2) DK2481405T3 (enExample)
ES (2) ES2576289T3 (enExample)
HU (1) HUE028472T2 (enExample)
IL (2) IL198576A (enExample)
MX (1) MX2009004803A (enExample)
NO (1) NO343908B1 (enExample)
NZ (1) NZ576856A (enExample)
PL (2) PL2481405T3 (enExample)
PT (2) PT2481405E (enExample)
RU (2) RU2009121568A (enExample)
SI (2) SI2481405T1 (enExample)
WO (1) WO2008057562A1 (enExample)
ZA (1) ZA200903132B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102263606B1 (ko) 2020-02-11 2021-06-10 충북대학교 산학협력단 파클리탁셀과 알피늄이소플라본을 함유한 나노 마이셀, 이의 제조방법 및 이의 용도

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US20070117863A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
DK1023050T3 (da) * 1997-06-27 2013-10-14 Abraxis Bioscience Llc Nye formuleringer af farmakologiske midler, fremgangsmåder til fremstillingen deraf og fremgangsmåder til anvendelsen deraf
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
CN103285395A (zh) * 2005-02-18 2013-09-11 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CN101291658B (zh) * 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
LT3311805T (lt) * 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
ES2406929T3 (es) * 2006-06-26 2013-06-10 The University Of British Columbia Proteína secretada ácida y rica en cisteína (SPARC) como sensibilizantes quimioterapéuticos
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
JP2010508277A (ja) * 2006-11-01 2010-03-18 ジョージ メイソン インテレクチュアル プロパティーズ，インコーポレイテッド オブ フェアファックス，バージニア 癌を検出および抑制するための方法
SI2117520T1 (sl) * 2006-12-14 2019-01-31 Abraxis Bioscience, Llc Zdravljenje raka dojk glede na status hormonskih receptorjev z nano delci, ki zajemajo taksan
CA3201293A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
CA2686736A1 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension
AU2008260447B2 (en) * 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
AU2008269179A1 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without Tween 80
ITMI20080284A1 (it) * 2008-02-22 2009-08-23 Indena Spa Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono
AU2009234127B2 (en) * 2008-04-10 2015-04-30 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
WO2010003057A2 (en) 2008-07-03 2010-01-07 Mayo Foundation For Medical Education And Research Treating cancer
EP2153821A1 (en) * 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
CN102281875B (zh) * 2009-01-16 2017-09-22 里格尔药品股份有限公司 预防、治疗或应对转移癌的使用axl抑制剂的组合疗法
BRPI1008955A2 (pt) * 2009-03-13 2015-09-01 Abraxis Bioscience Llc Terapia de combinação com derivados de tiocolchicina.
ES2764100T3 (es) 2009-04-15 2020-06-02 Abraxis Bioscience Llc Composiciones de nanopartículas exentas de priones y métodos
JP2012532879A (ja) * 2009-07-07 2012-12-20 ノームオキシーズ，インコーポレイテッド イノシトールトリピロリン酸を使用して多剤耐性を低減する方法
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
SG183414A1 (en) * 2010-02-23 2012-09-27 Genentech Inc Anti-angiogenesis therapy for the treatment of ovarian cancer
EP2552438B1 (en) 2010-03-26 2016-05-11 Abraxis BioScience, LLC Methods of treatment of hepatocellular carcinoma
CA2794147A1 (en) * 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
BR112012024442A2 (pt) * 2010-03-29 2017-03-21 Abraxis Bioscience Llc métodos de tratamento de câncer
RU2576609C2 (ru) 2010-06-04 2016-03-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечение рака поджелудочной железы
EP3056201A1 (en) * 2010-06-07 2016-08-17 Abraxis BioScience, LLC Combination therapy methods for treating proliferative diseases
US20120121510A1 (en) * 2010-11-11 2012-05-17 Brem Rachel F Localized therapy following breast cancer surgery
US20130323265A1 (en) * 2010-11-15 2013-12-05 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with dll4 antagonists
HRP20200793T1 (hr) 2011-05-09 2020-10-16 Mayo Foundation For Medical Education And Research Liječenje raka
EP2773322A1 (en) 2011-11-01 2014-09-10 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
WO2013085902A1 (en) 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
HUE045661T2 (hu) 2011-12-14 2020-01-28 Abraxis Bioscience Llc Polimer segédanyagok alkalmazása részecskék liofilizálásához vagy fagyasztásához
RS58964B1 (sr) 2012-03-13 2019-08-30 Hoffmann La Roche Kombinovana terapija za lečenje karcinoma jajnika
WO2014055415A1 (en) * 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
NZ630239A (en) * 2013-02-11 2017-08-25 Abraxis Bioscience Llc Methods of treating melanoma
EP2968254B1 (en) 2013-03-12 2020-04-22 Abraxis BioScience, LLC Methods of treating lung cancer
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
US10842969B2 (en) 2013-10-25 2020-11-24 Mercator Medsystems, Inc. Systems and methods of treating malacia by local delivery of hydrogel to augment tissue
WO2015134543A1 (en) * 2014-03-05 2015-09-11 Sorrento Therapeutics, Inc. Pharmacokinetically equivalent nanoparticle compositions
EP2924022A1 (en) * 2014-03-27 2015-09-30 INDENA S.p.A. Amorphous form of a thiocolchicine derivative
EP3154586B1 (en) 2014-06-13 2020-05-27 Mayo Foundation for Medical Education and Research Treating lymphomas
MX2016016617A (es) 2014-06-16 2017-03-23 Mayo Foundation Tratamiento de mielomas.
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
WO2015018380A2 (en) * 2014-07-03 2015-02-12 Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. Therapeutic nanoparticles and the preparation methods thereof
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
KR102008859B1 (ko) * 2014-10-06 2019-08-08 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 담체-항체 조성물 및 그의 제조 및 사용 방법
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
LT3313401T (lt) 2015-06-29 2022-01-10 Abraxis Bioscience, Llc Nanodalelės, apimančios sirolimą ir albuminą, skirtos naudoti epitelioidinių ląstelių navikų gydymui
WO2017176265A1 (en) * 2016-04-06 2017-10-12 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
AU2016308337B2 (en) * 2015-08-18 2019-02-28 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
CN105288639A (zh) * 2015-11-23 2016-02-03 中国药科大学 一种载阿霉素的主动靶向白蛋白纳米载体的制备及其应用
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
US11351254B2 (en) 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
CA3018340A1 (en) * 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
CA3018341A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
RU2019105550A (ru) * 2016-08-05 2020-09-07 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Модифицированные комплексы с наночастицами антитело-альбумин для лечения злокачественного новообразования
EP3505165B1 (en) * 2016-08-26 2025-11-26 Tetsuji Okuno Method of producing a fine nano-sized medicinal agent
KR20220151022A (ko) 2016-09-01 2022-11-11 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물
MX2019002473A (es) 2016-09-01 2019-09-18 Mayo Found Medical Education & Res Métodos y composiciones para el direccionamiento de cánceres de células t.
CA3035655A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Methods of treating pd-l1 expressing cancer
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CA3035653A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
CN106310291A (zh) * 2016-09-14 2017-01-11 东南大学 主动靶向抗肿瘤纳米药物及其制备方法和应用
CA3041049A1 (en) 2016-10-27 2018-05-03 Celgene Quanticel Research, Inc. Bromodomain and extra-terminal protein inhibitor combination therapy
CA3042238C (en) * 2016-10-28 2021-08-10 Nant Holdings Ip, Llc Avatar dendritic cells: the neoantigen natural killer t-cell chemo immuno radiation composition inducing immunogenic cell death
US11730736B2 (en) 2017-11-06 2023-08-22 Rapt Therapeutics, Inc. Anticancer agents
US20200390717A1 (en) * 2017-11-21 2020-12-17 University Of Iowa Research Foundation Synthetically lethal nanoparticles for treatment of cancers
CA3084994A1 (en) * 2017-12-19 2019-06-27 Abraxis Bioscience, Llc Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy
EA202091786A1 (ru) 2018-01-26 2020-10-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс
BR112020018910A2 (pt) 2018-03-20 2020-12-29 Abraxis Bioscience, Llc Métodos de tratamento de transtorno do sistema nervoso central através da administração de nanopartículas de um unibidor de mtor e de uma albumina
JP2022553426A (ja) 2019-10-28 2022-12-22 アブラクシス バイオサイエンス， エルエルシー アルブミンおよびラパマイシンの医薬組成物
KR20220104756A (ko) 2019-11-25 2022-07-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구내 신생혈관형성을 위한 장기지속형 vegf 억제제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006089290A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470571A (en) 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
IL98528A0 (en) 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
ATE247168T1 (de) 1991-03-06 2003-08-15 Merck Patent Gmbh Humanisierte monoklonale antikörper
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
AU1831395A (en) 1994-01-14 1995-08-01 Cell Therapeutics, Inc. Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
DK1325932T5 (da) 1997-04-07 2005-10-03 Genentech Inc Anti-VEGF antistoffer
ES2279614T3 (es) 1998-04-16 2007-08-16 Eurovita A/S Nuevas composiciones sinergicas que contienen compuestos aromaticos y terpenoides presentes en alpinia galanga.
AU777528B2 (en) 1999-04-22 2004-10-21 Abraxis Bioscience, Llc Long term administration of pharmacologically active agents
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
US20040143004A1 (en) 2002-02-26 2004-07-22 Joseph Fargnoli Metronomic dosing of taxanes
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
MXPA05012723A (es) * 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
JP2007505938A (ja) * 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Ｖｅｇｆ受容体阻害剤と化学療法剤の組み合わせ
US20060003931A1 (en) 2004-05-06 2006-01-05 Genentech, Inc. Crystal structure of the hepatocyte growth factor and methods of use
MY194883A (en) 2004-06-04 2022-12-21 Genentech Inc Method for treating multiple sclerosis
GT200500155A (es) 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
US8772269B2 (en) * 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
WO2006077424A1 (en) * 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
CN101232901B (zh) * 2005-02-28 2011-12-07 卫材R&D管理有限公司 磺酰胺化合物和血管生成抑制物质的联合新应用
CN101291658B (zh) * 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
LT3311805T (lt) * 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006089290A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ClinicalTrials Identifier: NCT00281528, ClinicalTrials.gov archive (2006.10.06.)*

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102263606B1 (ko) 2020-02-11 2021-06-10 충북대학교 산학협력단 파클리탁셀과 알피늄이소플라본을 함유한 나노 마이셀, 이의 제조방법 및 이의 용도

Also Published As

Publication number Publication date
IL198576A0 (en) 2010-02-17
KR20170016017A (ko) 2017-02-10
DK2481405T3 (en) 2016-06-06
AU2007317859A1 (en) 2008-05-15
NO343908B1 (no) 2019-07-01
NZ576856A (en) 2012-06-29
IL244390A0 (en) 2016-04-21
EP3108885A1 (en) 2016-12-28
HUE028472T2 (en) 2016-12-28
BRPI0718528A2 (pt) 2013-11-19
SI2097078T1 (sl) 2014-07-31
JP5931323B2 (ja) 2016-06-08
JP2016014073A (ja) 2016-01-28
CN101573108A (zh) 2009-11-04
RU2013149282A (ru) 2015-05-10
CA2668607A1 (en) 2008-05-15
SI2481405T1 (sl) 2016-08-31
CY1115271T1 (el) 2017-01-04
ZA200903132B (en) 2010-08-25
PT2097078E (pt) 2014-07-25
RU2009121568A (ru) 2010-12-20
JP2010509331A (ja) 2010-03-25
DK2097078T3 (da) 2014-05-12
CN104940929A (zh) 2015-09-30
EP2481405B1 (en) 2016-03-23
KR20180012339A (ko) 2018-02-05
NO20092179L (no) 2009-08-06
AU2007317859B2 (en) 2013-07-25
ES2576289T3 (es) 2016-07-06
PL2481405T3 (pl) 2016-09-30
PT2481405E (pt) 2016-06-08
US20070166388A1 (en) 2007-07-19
WO2008057562A1 (en) 2008-05-15
IL244390A (en) 2017-04-30
MX2009004803A (es) 2009-07-09
RU2673805C2 (ru) 2018-11-30
CY1117725T1 (el) 2017-05-17
KR20150065957A (ko) 2015-06-15
EP2481405A1 (en) 2012-08-01
IL198576A (en) 2016-12-29
JP2014043454A (ja) 2014-03-13
EP2097078B1 (en) 2014-04-16
KR20090087906A (ko) 2009-08-18
HK1173976A1 (en) 2013-05-31
ES2469716T3 (es) 2014-06-18
PL2097078T3 (pl) 2014-09-30
EP2097078A1 (en) 2009-09-09

Similar Documents

Publication Publication Date Title
KR101857142B1 (ko) 암에 대항하는 베바시주맙과 조합된 파클리탁셀 및 알부민의 나노입자
KR101914254B1 (ko) 치료제의 조합 및 투여 방식, 및 조합 요법
US20200316216A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
US20100112077A1 (en) Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
AU2016204834B2 (en) Combinations and modes of administration of therapeutic agents and combination therapy
AU2013204181A1 (en) Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
HK1232772A1 (en) Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
HK1134256B (en) Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
HK1134256A (en) Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
HK1173976B (en) Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170131

Application number text: 1020157014446

Filing date: 20150529

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170302

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170512

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20171122

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170512

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20171222

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20171122

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2017101006144

Request date: 20171222

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180122

Application number text: 1020157014446

Filing date: 20150529

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20171222

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20171222

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20170712

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20180207

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20180123

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180504

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180508

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20210415

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230418

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240402

Start annual number: 7

End annual number: 7